nanoTherics, Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
nanoTherics, Ltd. - overview
Established
2007
Location
Newcastle under Lyme, -, UK
Primary Industry
Biotechnology
About
nanoTherics, Ltd. develops advanced magnetic hyperthermia equipment, focusing on innovative solutions for research and healthcare applications. Their flagship magneTherm system allows versatile operations in magnetic nanoparticle heating and drug delivery. Founded in 2007 and headquartered in Newcastle under Lyme, UK, nanoTherics, Ltd.
is dedicated to creating state-of-the-art magnetic hyperthermia technologies. The company has raised GBP 262,000 in venture funding as of January 6, 2016, which has been pivotal for its growth, valuing the company at GBP 2. 08 million. The CEO, Carl Jones, has been instrumental in navigating the company's strategies and expansion efforts across multiple global markets.
nanoTherics Ltd specializes in developing and providing advanced magnetic hyperthermia equipment, with a focus on their flagship product, the magneTherm system. This platform supports multiple applications, including calorimetric studies, in vitro and in vivo research, and drug delivery systems. The magneTherm system is customizable according to user specifications and serves clients globally, including leading academic institutions and healthcare providers across North America, Europe, Asia, and Australia. The revenue model of nanoTherics primarily revolves around the sale of its magneTherm systems and associated accessories to institutional clients, including universities and research facilities.
These transactions often align with grant funding for scientific research. While specific pricing details are undisclosed, the product range incorporates customizable options and upgrades, fostering long-term relationships through ongoing support and ancillary consumables. The successful integration of the magneTherm system into diverse applications is evidenced by sales across 27 countries, reinforcing its position in the magnetic hyperthermia sector. In January 2016, nanoTherics, Ltd.
raised GBP 262,000 in venture funding, which will be utilized to further develop its product offerings and expand into new geographic markets. The company aims to enhance its product lineup and is focusing on specific regions, including North America and Asia, for market expansion. This funding round has positioned nanoTherics for strategic growth, leveraging its recent innovations and broadening its client base.
Current Investors
Mercia Fund Management, WM Enterprise Investment Division, Catapult Ventures Group
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.nanotherics.com
Verticals
Nanotechnology
Company Stage
Series B
Total Amount Raised
Subscriber access only
nanoTherics, Ltd. - financials
| Fiscal Year Ended | Aug 31, 2017 | Aug 31, 2018 |
|---|---|---|
| Revenue (USD) | - | - |
| % Revenue Growth (YoY) | - | - |
| EBITDA (USD) | - | - |
| Operating Income (USD) | - | - |
| Operating Margin | - | - |
| % EBITDA Margin | - | - |
| NET Income (USD) | - | - |
| % Net Margin | - | - |
nanoTherics, Ltd. - employee data


Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.